ZyCoV-D® is the world’s first plasmid DNA vaccine for human use that has been developed in India and given restricted use license for emergency situation that grants permission for the vaccine to be used for active immunization of individuals aged 12 years and older for the prevention of coronavirus disease 2019 (COVID-19).1-4
ZyCoV-D® vaccination schedule consists of 3 separate doses to be given at an interval of 28 days each (day 0, day 28 and day 56).Each dose consists of two shots of 0.1ml each given by needle-free injector (PharmaJet Tropis device) via intradermal route at two separate sites (preferably deltoid region of both the arms).4
Key Features of ZyCoV-D®
Zydus Vaccines – Heritage Across Decades
About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines. The group employs 25,000 people worldwide and is dedicated to creating healthier communities globally. For more information, please visit www.zyduscadila.com
Zydus’ multi-pronged approach to combat the COVID-19 pandemic
Zydus’ Vaccine Research Program
Vaccine Technology Centre of Zydus Cadila has wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate and other subunit vaccines for unmet needs.
In fact, Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu during the pandemic in 2010. In past, it has also indigenously developed numerous vaccines successfully including tetravalent seasonal influenza vaccine (first company in India to indigenously develop and commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine (first Indian company to indigenously develop and receive market authorization), Measles containing vaccines (MR, MMR), Typhoid conjugate vaccine, pentavalent vaccine (DPT-HepB-Hib) to name a few.